Diagnosing Charcot-Marie-Tooth disease (CMT) typically involves a combination of a physical exam, nerve conduction studies, and genetic testing. Because CMT is inherited and progresses slowly, many people live with symptoms for years before getting a definitive diagnosis. The process usually unfolds in stages, starting with visible signs and working toward a genetic confirmation that identifies the exact type.
What Doctors Look for During a Physical Exam
The first step is usually a neurological exam where a doctor checks for the hallmark physical signs of CMT. These include weakness in the legs, ankles, and feet, high foot arches, curled toes (hammertoes), and muscle wasting in the lower legs. The pattern of muscle loss in the calves is distinctive enough to have its own description: the legs can look like upside-down champagne bottles, with normal-sized thighs tapering to unusually thin calves.
A doctor will also watch how you walk. Foot drop, where you can’t lift the front of your foot properly, is a common finding. This causes a high-stepping gait and frequent tripping. Reflexes at the ankle are typically reduced or absent. In more advanced cases, weakness and sensory changes spread to the hands and forearms, making fine motor tasks like buttoning a shirt difficult.
In children, the earliest signs may be subtle: clumsiness, difficulty running, or unusually high arches noticed during a routine checkup. These orthopedic clues often prompt a referral to a neurologist for further testing.
Nerve Conduction Studies and EMG
Once a doctor suspects CMT, the next step is electrodiagnostic testing. This usually means two related tests: a nerve conduction study (NCS) and electromyography (EMG). Together, they reveal whether the problem lies in the nerve’s insulating coating (myelin), the nerve fiber itself, or both, which helps narrow down the CMT subtype before genetic testing even begins.
During a nerve conduction study, electrodes are placed on your skin above a nerve and a small electrical pulse is sent through. The test measures how fast and how strongly the signal travels. In demyelinating forms of CMT (like CMT1), nerve conduction speeds are significantly slower than normal. In axonal forms (like CMT2), the speed may be closer to normal, but the strength of the signal is reduced. A nerve conduction study takes anywhere from 15 minutes to over an hour depending on how many nerves are tested. Most people describe the electrical pulses as a mild tingling, similar to static electricity.
An EMG tests the muscles themselves. A thin needle electrode is inserted into a muscle, and electrical activity is recorded both at rest and while you gently contract the muscle. This helps determine whether muscle weakness is coming from nerve damage or from a muscle problem. The needle insertion can cause slight pain, and the test takes 30 to 60 minutes. Your muscles may feel sore for a few days afterward, and minor bruising at the needle sites is normal.
These electrodiagnostic results are critical because they guide which genetic tests to order. A neurologist who sees uniformly slow nerve conduction across all nerves, for example, will focus genetic testing on demyelinating CMT genes rather than casting a wide net.
Genetic Testing for Confirmation
Genetic testing is the definitive way to confirm CMT and identify the specific type. It requires only a blood sample. Results typically take about four to six weeks from a specialized laboratory, though turnaround can vary.
The genes tested depend on the suspected subtype. For CMT1, the most common form, 70 to 80 percent of cases involve mutations in the PMP22 gene, which provides instructions for a protein critical to the nerve’s myelin sheath. Another 10 to 12 percent of CMT1 cases trace to mutations in the MPZ gene. For CMT2 (the axonal form), mutations in the MFN2 gene account for roughly 20 percent of cases. For X-linked CMT, about 90 percent of cases involve mutations in the GJB1 gene.
Labs often use tiered panels, testing the most common mutations first and expanding to rarer genes if those come back negative. Comprehensive CMT panels that screen dozens of genes at once are also available. Insurance often covers genetic testing when a doctor orders it, though coverage policies vary by plan. Some people choose to pay out of pocket, and it’s worth calling your insurer before the test to confirm what’s covered.
It’s worth knowing that genetic testing doesn’t find a mutation in every person with CMT. Over 100 genes have been linked to CMT so far, and some cases involve genes that haven’t been identified yet. A negative genetic test doesn’t rule out CMT if the clinical picture and nerve studies fit.
Ruling Out Other Conditions
Part of diagnosing CMT means making sure something else isn’t causing the neuropathy. Several conditions can look similar on the surface, and distinguishing them matters because their treatments differ significantly.
Diabetic neuropathy is one of the most common sources of confusion. CMT is frequently misdiagnosed as diabetic neuropathy in people who happen to have diabetes. The key difference: diabetic neuropathy is primarily a sensory problem (numbness, tingling, pain) and rarely causes significant muscle weakness. It also tends to come alongside other diabetic complications like eye or kidney disease.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is another look-alike. CIDP is an autoimmune condition where the immune system attacks nerve myelin, producing slow nerve conduction that can mimic CMT1 on electrodiagnostic testing. This distinction is important because CIDP responds to immune-suppressing treatment, while CMT does not. In difficult cases, a nerve biopsy, where a small piece of nerve is surgically removed and examined under a microscope, can help tell the two apart. Nerve biopsy is rarely needed for a straightforward CMT diagnosis and is generally reserved for situations where an acquired, treatable condition is being considered.
Certain inherited muscle diseases and motor neuron disorders can also mimic CMT by causing symmetric weakness in the lower legs and feet. A clue that points away from CMT and toward these conditions is the preservation of ankle reflexes and normal sensation, both of which are typically affected in CMT.
Why Early Diagnosis Matters
CMT has no cure, but identifying it early and accurately still makes a practical difference. People with CMT are more susceptible to worsening from additional nerve stresses, including diabetes and certain chemotherapy drugs. Knowing you have CMT allows your medical team to avoid neurotoxic medications and monitor for complications proactively.
A confirmed genetic diagnosis also has implications for family planning. CMT follows different inheritance patterns depending on the type. Some forms require only one copy of a mutated gene from one parent, while others require copies from both parents, and X-linked forms affect men and women differently. Genetic counseling after a confirmed diagnosis helps family members understand their own risk and testing options.
Physical therapy, bracing, and in some cases orthopedic surgery for foot deformities are the mainstays of management. Starting these interventions earlier, guided by an accurate subtype diagnosis, helps preserve mobility and quality of life over the long term.